Neocorp Media Inc

The Medical Letter, Inc. is a trusted and authoritative source of medical information, providing healthcare professionals with unbiased and evidence-based reviews of drugs and treatments. With a focus on delivering the latest research and clinical findings, they offer a comprehensive range of publications, including a current issue, previous issues, reference tables, and sample articles. Their dedication to continuing education is evident through their exams and drug interactions resources, ensuring healthcare professionals stay up-to-date with the latest developments in the field. As pioneers in the industry, The Medical Letter, Inc. has recently gained FDA approval for daprodustat Jesduvroq, the first hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) and oral drug for the treatment of anemia in adults with chronic kidney disease (CKD) who have been on dialysis for at least 4 months. They continue to expand their portfolio, with recent approvals for cantharidin topical solution Ycanth and berdazimer gel formulation Zelsuvmi, providing innovative treatment options for molluscum contagiosum in patients of different age groups.Generated from the website